Caption Management’s Akebia Therapeutics AKBA Stock Holding History

Caption Management’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$34.3K	Hold	24,692	–	–	﹤0.01%	1435
2025 Q4	$39.8K	Buy	+24,692	New	+$51.7K	﹤0.01%	1475
2022 Q1	–	Sell	-210,000	Closed	-$449K	–	1425
2021 Q4	$475K	Buy	+210,000	New	+$573K	0.01%	1258
2020 Q3	–	Sell	-50,000	Closed	-$678K	–	1005
2020 Q2	$678K	Buy	50,000 +10,000	+25%	+$103K	0.02%	624
2020 Q1	$303K	Sell	40,000 -50,531	-56%	-$393K	0.02%	637
2019 Q4	$572K	Buy	90,531 +17,031	+23%	+$80.9K	0.02%	607
2019 Q3	$288K	Hold	73,500	–	–	0.02%	557
2019 Q2	$356K	Buy	73,500 +67,500	+1,125%	+$384K	0.02%	516
2019 Q1	$49K	Buy	+6,000	New	+$41.2K	﹤0.01%	536

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Caption Management's AKBA Position: Q1 2026 in Review

Caption Management held its Akebia Therapeutics (AKBA) position steady in Q1 2026 at 24,692 shares worth $34.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1435.

Caption Management first reported a position in AKBA in Q1 2019 and has held it in 9 quarters since. The position peaked at $678K in Q2 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

Caption Management held 24,692 shares of Akebia Therapeutics worth $34.3K as of Q1 2026.
Caption Management left its Akebia Therapeutics share count unchanged in Q1 2026.
Akebia Therapeutics made up ﹤0.01% of Caption Management's portfolio in Q1 2026, its #1435 holding.
Caption Management first reported a position in Akebia Therapeutics in Q1 2019 and has held it in 9 quarters since.
Caption Management's Akebia Therapeutics position peaked at $678K in Q2 2020.
171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.